Aceragen, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $4.9M | $0 | — | $1.4M | $662,000 | $902,000 |
| Operating income | −$27.8M | −$27.7M | −$36.7M | −$46.1M | −$61.0M | −$66.5M |
| Net income | −$23.4M | $98.1M | −$112.7M | −$56.5M | −$59.9M | −$66.0M |
| Total assets | $101.1M | $34.9M | $42.4M | $47.5M | $73.0M | $118.4M |
| Total liabilities | $62.2M | $5.4M | $133.6M | $58.7M | $9.0M | $10.7M |
| Equity | $11.8M | $29.5M | −$91.2M | −$11.2M | $64.0M | $107.7M |
| EPS (diluted) | $-7.18 | $-9.78 | $-3.33 | $-2.96 | — | — |
| Shares out. | 52.9M | 42.3M | 30.5M | 27.6M | 195.6M | 149.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −572.2%
- Net margin
- −480.5%
- Return on equity
- −197.5%
- Return on assets
- −23.1%
- Return on capital (ROCE)
- −34.9%
- Liabilities / assets
- 61.5%
- Debt / equity
- 5.26×
- Book value / share
- $0.22
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- −123.8%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -26.35distress
- Accruals / assets
- 1.1%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2023
- NT 10-Kmissed a reporting deadline ↗Apr 3, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Gowen MaxineDirector | Aug 10, 2023 | Sell | 51 | $0.51 |
| Milano VincentDirector | Aug 10, 2023 | Sell | 3,283 | $0.53 |
| Pillar Invest Corp10% owner | May 17, 2023 | Buy | 26,965 | $1.42 |
| Pillar Invest Corp10% owner | Jul 12, 2023 | Sell | 3,605 | $1.58 |
| Chopra Atul10% owner | May 15, 2023 | Sell | 6,887 | $1.40 |
| Chopra Atul10% owner | May 12, 2023 | Sell | 23,890 | $1.50 |
| Chopra Atul10% owner | May 11, 2023 | Sell | 3,734 | $1.75 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder vote · Other material eventAug 16, 2023
- Director / officer changeJul 21, 2023
- Other material eventJul 11, 2023
- Delisting / listing-standard noticeMay 30, 2023
- Costs from exit or disposal · Director / officer change · Other material eventMay 4, 2023
- Director / officer changeMar 30, 2023
- Other material eventFeb 6, 2023
- Entered a material agreement · Unregistered equity sale · Director / officer changeFeb 3, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.